{[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl}amine trifluoroacetate, 95.0%, 10g

3-Nitro-N-(piperidin-4-ylmethyl)pyridin-2-amine hydrochloride, 95.0%, 1g

3-Hydroxy-2,2-dimethylpropanenitrile, 95.0%, 500mg

1-(Benzyloxy)-3-(bromomethyl)benzene, 95.0%, 1g

(1S)-2′-[(Dicyclohexylamino)carbonyl][1,1′-binaphthalene]-2-carboxylic acid, 100mg

Di-tert-butyl 3,3'-azanediyldipropanoate, 97.0%, 100mg

1-(2-Methoxyphenyl)cyclobutane-1-carboxylic acid, 95.0%, 1g

(2E)-1-(4-ethylphenyl)-3-(3-fluorophenyl)prop-2-en-1-one, 95.0%, 2g

trans-2-Phenyl-1-cyclopropanecarboxylic Acid>98.0%(T)25g

Ethyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate, 95.0%, 5g

Solución de sal disódica de EDTA, volumen ROTI® 0,01 mol/l - 0,01 N, ampolla, 1 pieza

bis(4-chloro-3-nitrophenyl) sulfone, 5g

Fmoc-D-2,6-Dimethyltyrosine, 98%, 250mg